Patents by Inventor Jing-Ping Liou

Jing-Ping Liou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINONAPHTHOQUINONE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
    Publication number: 20240130984
    Abstract: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Yun YEN, Jing-Ping LIOU, Chien Huang LIN
  • Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
    Patent number: 11919858
    Abstract: The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 5, 2024
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • Soluble honokiol derivatives
    Patent number: 11903907
    Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 20, 2024
    Assignees: TAIPEI MEDICAL UNIVERSITY, CATHAY GENERAL HOSPITAL
    Inventors: Joen-Rong Sheu, Fa-Kung Lee, Chih-Cheng Chien, Chih-Ming Ho, Chao-Chien Chang, Cheng-Ying Hsieh, Jing-Ping Liou
  • Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
    Patent number: 11833122
    Abstract: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 5, 2023
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Chien Huang Lin
  • Heat shock protein 90 inhibitors
    Patent number: 11479528
    Abstract: This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: October 25, 2022
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Jing-ping Liou, Che-ming Teng, Shiow-lin Pan
  • Histone deacetylase 6 inhibitors and use thereof
    Patent number: 11427544
    Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 30, 2022
    Assignees: TAIPEI MEDICAL UNIVERSITY, NATIONAL TAIWAN UNIVERSITY
    Inventors: Che-Ming Teng, Jing-Ping Liou, Shiow-Lin Pan, Chia-Ron Yang
  • HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN
    Publication number: 20220251043
    Abstract: Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 11, 2022
    Applicant: Taipei Medical University
    Inventors: Shiow-Lin PAN, Chia-Ron YANG, Han-Li HUANG, Huang-Ju TU, Jing-Ping LIOU
  • INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
    Publication number: 20220184032
    Abstract: The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Chien Huang LIN, Jing-Ping LIOU, Shiow-Lin PAN, Che-Ming TENG
  • Indoline derivatives for treatment and/or prevention of fibrosis diseases
    Patent number: 11278523
    Abstract: The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 22, 2022
    Assignee: Taipei Medical University
    Inventors: Chien Huang Lin, Jing-Ping Liou, Shiow-Lin Pan, Che-Ming Teng
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 11084786
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 10, 2021
    Assignee: CALGENT BIOTECHNOLOGY CO., LTD.
    Inventors: Yun Yen, Jing-Ping Liou, Shiow-Lin Pan
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
    Publication number: 20200385344
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 10, 2020
    Inventors: Yun YEN, Jing-Ping LIOU, Shiow-Lin PAN
  • SOLUBLE HONOKIOL DERIVATIVES
    Publication number: 20200358554
    Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 12, 2020
    Inventors: JOEN-RONG SHEU, FA-KUNG LEE, CHIH-CHENG CHIEN, CHIH-MING HO, CHAO-CHIEN CHANG, CHENG-YING HSIEH, JING-PING LIOU
  • Compounds for inhibiting cancer and virus
    Patent number: 10745433
    Abstract: The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 18, 2020
    Assignee: Taipei Medical University
    Inventors: Yun Yen, Jing-Ping Liou, Yun-Ru Liu
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 10745350
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: July 30, 2016
    Date of Patent: August 18, 2020
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES
    Publication number: 20200148643
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN
  • Chlorobenzene substituted azaaryl compounds
    Patent number: 10624897
    Abstract: The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cancer and liver cancer.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 21, 2020
    Assignee: Taipei Medical University
    Inventors: Yun Yen, Jing-Ping Liou, Chun-Han Chen
  • Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
    Patent number: 10577328
    Abstract: The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 3, 2020
    Assignee: Taipei Medical University
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • HEAT SHOCK PROTEIN 90 INHIBITORS
    Publication number: 20200039923
    Abstract: This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: March 20, 2018
    Publication date: February 6, 2020
    Inventors: Jing-ping LIOU, Che-ming TENG, Shiow-lin PAN
  • HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF
    Publication number: 20190284141
    Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 19, 2019
    Applicant: DCB-USA LLC
    Inventors: Che-Ming TENG, Jing-Ping LIOU, Shiow-Lin PAN, Chia-Ron YANG
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
    Publication number: 20190144383
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Application
    Filed: July 30, 2016
    Publication date: May 16, 2019
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN